Marstacimab injection | China Drugs List

Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.

Company: Pfizer Inc.
Medicine type: Biologic
Therapeutic area: Non-malignant blood disorders
Indications recorded in the public source: Routine prophylaxis to prevent or reduce the frequency of bleeding in adults and children aged 12 years or older weighing at least 35 kg with: 1. Severe hemophilia A (congenital factor VIII deficiency, FVIII <1%) without factor VIII inhibitors. 2. Severe hemophilia B (congenital factor IX deficiency, FIX <1%) without factor IX inhibitors.
Indication source and scope: Source date(s): 2026. Indications reflect the cited historical approval, not the complete indication set as of 2026.
Prescribing-information limitations: Complete official prescribing information obtained. The available full label is from an overseas jurisdiction; a complete current Chinese label remains unavailable. Chinese indications are supported separately by Chinese sources.
China availability status: Historical Chinese approval verified; current continuous market availability has not been checked for every product.
Overseas status: Japan: local approval / launch announcements and official price sources obtained. Indications and dates are specified in each price record; other markets not exhaustively reviewed.
Insurance classification: Not matched in the 2025 national list; manual review pending
Insurance edition: 2025 edition; effective 1 January 2026
Insurance verification notes: No match in the extracted directory is not proof of exclusion. Compound formulations still require manual review.

Sources

Open the interactive record, public price references and discussions